Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:ACUTAAS

ACUTAAS CHEMICALS LIMITED

Healthcare › Pharmaceuticals & Biotechnology·NIFTY 500NIFTY MIDSMALLCAP 400NIFTY MIDSMALLCAP400 50:50NIFTY SMALLCAP 100+8
₹3,796.00
at close · 27 Oct 2026
▲ 446.70 (+13.34%)
ThemesBatteries & Energy Storage· growingSemiconductors & Electronics· announced

Latest filings

Next results: Tue, 27 Oct · Financial Results
  1. Earnings call recording for October 27, 2026 available on website · Investor Communications
  2. Q2 EBITDA jumps 84.6%; FY27 revenue and margin guidance raised · Investor Communications
  3. Q2 FY27 revenue up 42.7%, PAT up 71.4%, guidance raised · Compliance
All filings ↓
Ask Nexa about ACUTAAS CHEMICALS LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Makes specialty chemicals across four segments, with pharmaceutical intermediates the dominant business. Pharma intermediates contributed 87.7% of FY26 revenue (₹11,741 Mn), supplying advanced intermediates and CDMO products to global pharmaceutical customers; the segment grew 76.5% YoY in Q1 FY27 to ₹292.7 cr. Commodity chemicals accounted for 11.2% of FY26 revenue and are being deliberately phased out as lower-margin products are replaced by higher-margin specialty offerings. Semiconductor chemicals — where the company is India's only photoresist manufacturer — made up 1.2% of FY26 revenue, with a new IndiChem plant in Korea due to start commercial revenue from FY28. Battery chemicals commercial supply commenced in Q1 FY27 after trial runs, targeting full 4,000 MT capacity (2,000 MT VC + 2,000 MT FEC) within three years. The cost base is dominated by raw materials at 44.4% of FY26 revenue, with capex at 24.5% reflecting heavy capacity expansion across plants. Management has guided to 25% revenue growth for FY27 with stable margins.

Revenue mix · reported segments
Pharmaceutical Intermediates87.7%
Commodity Chemicals11.2%
Semiconductor Chemicals1.2%
Operating scale
Battery chemicals capacity
4,000 MT (2,000 MT VC + 2,000 MT FEC)FY27
Manufacturing facilities
5FY26
Employees
~1,000FY26
Global market share in key pharma intermediates
50-90%FY26
IndiChem semiconductor plant (Korea)
Commercial revenue expected from FY28FY28
CDMO revenue target
₹1,000 cr by FY28FY28
Who pays it
Global pharmaceutical companies for intermediates; semiconductor chip manufacturers for photoresist chemicals; battery and EV industry players for electrolyte additives
Biggest cost
Raw materials at 44.4% of FY26 revenue
Kind of business
Specialty chemicals manufacturer anchored by pharma intermediates, diversifying into battery and semiconductor chemicals
Where it sits
India's only manufacturer of photoresist chemicals and first electrolyte additives manufacturer; claims 50-90% global market share in key pharmaceutical intermediates
Market Cap
₹31,078 Cr
P / E (TTM)
80.5×
EV / EBITDA
54.2×
Div Yield
0.04%
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
18.5%▲
ROCE (5y median)
ROE 13.8% (5y median) · margin 39.0%
Leverage
0.02·
Debt / Equity · low
Net cash ₹189 Cr
Revenue FY22→FY26
2.6×▲
Margin +12.8 pts
₹520 Cr → ₹1,339 Cr
Cash conversion
0.82×·
Operating cash ÷ profit · 5 yrs
₹593 Cr on ₹721 Cr
Moves on a normal day
1.58%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#135/158
P/B#158/163
ROCE#12/183
ROE#17/166
Debt / Equity#50/166
EBITDA margin#19/165
Revenue growth#17/161
Profit growth#49/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Returns on capital 18.5% (5-year median)
#12 of 183 in Pharmaceuticals on the latest reported figures · up from 18.5% in FY22
Debt at 0.02× equity
lower than 70% of its 166 Pharmaceuticals peers
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

ACUTAAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from ACUTAAS CHEMICALS LIMITED's filed financials and exchange disclosures

What does ACUTAAS CHEMICALS LIMITED do?

ACUTAAS CHEMICALS LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ACUTAAS.

Is ACUTAAS CHEMICALS LIMITED profitable?

Yes. Over the trailing twelve months ACUTAAS CHEMICALS LIMITED reported a net profit of ₹387 Cr on revenue of ₹1,462 Cr.

Does ACUTAAS CHEMICALS LIMITED pay a dividend?

Yes. The dividend yield is 0.04% at the current price. It paid out 3% of its profit as dividend in FY26.

Is ACUTAAS CHEMICALS LIMITED debt-free?

On a net basis, yes. It reported borrowings of ₹26 Cr on its 31 Mar 2026 balance sheet, but holds ₹189 Cr more cash than debt.

Is ACUTAAS CHEMICALS LIMITED expensive compared with its peers?

On trailing P/E, ACUTAAS CHEMICALS LIMITED ranks 135 of 158 in Pharmaceuticals — cheaper than 15% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.

How much does the ACUTAAS CHEMICALS LIMITED share price move in a day?

On a typical session ACUTAAS CHEMICALS LIMITED moves 1.58% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

When are ACUTAAS CHEMICALS LIMITED's next results?

Financial Results on Tue, 27 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track ACUTAAS CHEMICALS LIMITED's announcements?

Every NSE and BSE filing by ACUTAAS CHEMICALS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.